Hypera (HYPE3) Q3 2025 earnings summary

Executive summary

• Net revenue reached R$2,227.2 million in 3Q25, up 16.3% year-over-year, driven by strong retail sell-out and working capital optimization.

• Retail sell-out grew 8.3% year-over-year, outpacing the market by 1.9 percentage points and improving 2.8 percentage points over 2Q25.

• Record operating cash flow reached R$853.6 million, supported by reduced working capital investments.

• EBITDA margin from continuing operations rose to 34.0%, reflecting improved operating leverage and product mix.

• Interest on Equity of R$185.1 million (R$0.29/share) approved for the quarter.

Financial highlights

• Gross margin improved to 61.2%, an increase of 140 basis points year-over-year.

• EBITDA from continuing operations rose 34.7% to R$756.2 million, margin at 34.0%.

• Net earnings from continuing operations were R$453.9 million, up 22.6% year-over-year.

• Free cash flow for 3Q25 was R$854 million.

• Net debt after hedge at R$7,268.8 million, or 2.4x annualized EBITDA.

Outlook and guidance

• Focus on sustainable growth through innovation, new product launches, and market share expansion in key categories.

• Pipeline includes launches in new markets, especially as patents expire (e.g., semaglutide, dapagliflozin).

• Confident in approval and launch of semaglutide post-patent expiry, aiming for branded product positioning.

• Expect operational cash flow to be lower in Q4 due to dividend and OTCP payments.

• Management highlights continued growth prospects, with forward-looking statements dependent on market conditions, regulations, and economic performance.